Puma Biotechnology (NASDAQ:PBYI) Upgraded at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of Puma Biotechnology (NASDAQ:PBYI – Free Report) from a buy rating to a strong-buy rating in a report released on Friday.

Puma Biotechnology Stock Down 1.6%

Puma Biotechnology stock opened at $5.03 on Friday. Puma Biotechnology has a fifty-two week low of $2.22 and a fifty-two week high of $6.07. The firm has a market capitalization of $253.36 million, a price-to-earnings ratio of 5.13 and a beta of 1.37. The stock’s fifty day moving average is $4.09 and its two-hundred day moving average is $3.51. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.62 and a current ratio of 1.73.

Insider Activity at Puma Biotechnology

In related news, Director Allison Dorval sold 11,610 shares of Puma Biotechnology stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $3.40, for a total transaction of $39,474.00. Following the completion of the transaction, the director directly owned 75,390 shares in the company, valued at $256,326. The trade was a 13.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Alessandra Cesano sold 27,000 shares of the stock in a transaction on Friday, July 18th. The shares were sold at an average price of $3.37, for a total value of $90,990.00. Following the sale, the director owned 41,850 shares in the company, valued at approximately $141,034.50. This trade represents a 39.22% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 173,649 shares of company stock valued at $596,914 in the last quarter. 23.30% of the stock is owned by corporate insiders.

Institutional Trading of Puma Biotechnology

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Wells Fargo & Company MN raised its position in shares of Puma Biotechnology by 36.5% in the fourth quarter. Wells Fargo & Company MN now owns 22,929 shares of the biopharmaceutical company’s stock valued at $70,000 after buying an additional 6,126 shares during the last quarter. Barclays PLC raised its holdings in Puma Biotechnology by 13.3% in the 4th quarter. Barclays PLC now owns 88,407 shares of the biopharmaceutical company’s stock valued at $270,000 after acquiring an additional 10,386 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Puma Biotechnology by 24.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 863,760 shares of the biopharmaceutical company’s stock worth $2,635,000 after purchasing an additional 170,968 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of Puma Biotechnology by 167.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 10,137 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 6,351 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Puma Biotechnology by 42.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 19,083 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 5,726 shares during the period. 61.29% of the stock is currently owned by hedge funds and other institutional investors.

Puma Biotechnology Company Profile

(Get Free Report)

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.

Read More